Cerebrospinal fluid levels of a proliferation-inducing ligand (APRIL) are increased in patients with neuropsychiatric systemic lupus erythematosus

Scandinavian Journal of Rheumatology

Volumn 40, Issue 5, 2011, Pages 363-372

  Hopia, L ^a   Thangarajh, M ^a   Khademi, M ^a   Laveskog, A ^a   Wallstrom E ^a   Svenungsson, E ^a   Andersson, M ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; APRIL PROTEIN; AZATHIOPRINE; B CELL ACTIVATING FACTOR; CYCLOPHOSPHAMIDE; MESSENGER RNA; METHOTREXATE; PREDNISOLONE; RITUXIMAB;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; FATIGUE; FATIGUE SEVERITY SCALE; FEMALE; GENE EXPRESSION; HUMAN; MALE; MULTIPLE SCLEROSIS; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS; NEUROPSYCHIATRY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RATING SCALE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGED; B-CELL ACTIVATING FACTOR; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FATIGUE; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13; YOUNG ADULT;

EID: 80053412207     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2010.550900     Document Type: Article

References (49)

1. Brey RL, Holliday SL, SakladAR,NavarreteMG, Hermosillo-Romo D, Stallworth CL, Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 2002;58:1214-20. (Pubitemid 34411865)
2. Hanly JG, Urowitz MB, Sanchez-Guerrero J, Bae SC, Gordon C, Wallace DJ, Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum 2007;56:265-73. (Pubitemid 46106200)
3. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599-608.
4. Scolding NJ, Joseph FG. The neuropathology and pathogenesis of systemic lupus erythematosus. Neuropathol Appl Neurobiol 2002;28:173-89. (Pubitemid 34639440)
5. Huizinga TW, Diamond B. Lupus and the central nervous system. Lupus 2008;17:376-9. (Pubitemid 351798711)
6. Brundin L, Svenungsson E, Morcos E, Andersson M, Olsson T, Lundberg I, et al. Central nervous system nitric oxide formation in cerebral systemic lupus erythematosus. Ann Neurol 1998;44:704-6. (Pubitemid 28477863)
7. Svenungsson E, Andersson M, Brundin L, van Vollenhoven R, Khademi M, Tarkowski A, et al. Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus. Ann Rheum Dis 2001;60:372-9. (Pubitemid 32242751)
8. Alcocer-Varela J, Aleman-Hoey D, Alarcon-Segovia D. Interleukin-1 and interleukin-6 activities are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlate with local late T-cell activation markers. Lupus 1992;1:111-17.
9. Hirohata S, Miyamoto T. Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum 1990;33:644-9. (Pubitemid 20166565)
10. Shiozawa S, Kuroki Y, Kim M, Hirohata S, Ogino T. Interferonalpha in lupus psychosis. Arthritis Rheum 1992;35:417-22.
11. DeGiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT, Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 2001;7:1189-93. (Pubitemid 33063773)
12. Kowal C, Degiorgio LA, Lee JY, Edgar MA, Huerta PT, Volpe BT, et al. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci USA 2006;103:19854-9. (Pubitemid 46037520)
13. Lai NS, Lan JL. Evaluation of cerebrospinal anticardiolipin antibodies in lupus patients with neuropsychiatric manifestations. Lupus 2000;9:353-7.
14. Svenungsson E, Gustafsson J, Leonard D, Sandling J, Gunnarsson I, Nordmark G, et al. A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus. Ann Rheum Dis 2009;69:834-40.
15. Toubi E, Khamashta MA, Panarra A, Hughes GR. Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus. Am J Med 1995;99:397-401.
16. Mackay F, Schneider P, Rennert P, Browning J. BAFF and APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003;21:231-64. (Pubitemid 37174532)
17. Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol 2006;18:263-75. (Pubitemid 44287558)
18. Dillon SR, Gross JA, Ansell SM, Novak AJ. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 2006;5:235-46. (Pubitemid 43336036)
19. Ingold K, Zumsteg A, Tardivel A, Huard B, Steiner QG, Cachero TG, et al. Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 2005;201:1375-83. (Pubitemid 40664082)
20. Koyama T, Tsukamoto H, Miyagi Y, Himeji D, Otsuka J, Miyagawa H, et al. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis 2005;64:1065-7. (Pubitemid 40909524)
21. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immunebased rheumatic diseases. Arthritis Rheum 2001;44:1313-19. (Pubitemid 32537529)
22. Jonsson MV, Szodoray P, Jellestad S, Jonsson R, Skarstein K. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjögren's syndrome. J Clin Immunol 2005;25:189-201. (Pubitemid 40884044)
23. Thangarajh M, Masterman T, Rot U, Duvefelt K, Brynedal B, Karrenbauer VD, et al. Increased levels of APRIL (a proliferationinducing ligand) mRNA in multiple sclerosis. J Neuroimmunol 2005;167:210-14. (Pubitemid 41242304)
24. www.hgsi.com/belimumab.html, accessed 2 March 2011.
25. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7. (Pubitemid 13221242)
26. Khademi M, Illes Z, Gielen AW, Marta M, Takazawa N, Baecher- Allan C, et al. T cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis. J Immunol 2004;172:7169-76. (Pubitemid 38669161)
27. Mattsson M, Moller B, Lundberg I, Gard G, Bostrom C. Reliability and validity of the Fatigue Severity Scale in Swedish for patients with systemic lupus erythematosus. Scand J Rheumatol 2008;37:269-77. (Pubitemid 351962337)
28. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 1987;149:351-6. (Pubitemid 17104996)
29. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The Fatigue Severity Scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121-3. (Pubitemid 19246303)
30. Roelcke U, Kappos L, Lechner-Scott J, Brunnschweiler H, Huber S, Ammann W, et al. Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18Ffluorodeoxyglucose positron emission tomography study. Neurology 1997;48:1566-71.
31. Tellez N, Rio J, Tintore M, Nos C, Galan I, Montalban X. Does the Modified Fatigue Impact Scale offer a more comprehensive assessment of fatigue in MS? Mult Scler 2005;11:198-202. (Pubitemid 40403260)
32. George-Chandy A, Trysberg E, Eriksson K. Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms. Arthritis Res Ther 2008;10:R97.
33. Krumbholz M, Theil D, Derfuss T, Rosenwald A, Schrader F, Monoranu CM, et al. BAFF is produced by astrocytes and upregulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 2005;201:195-200. (Pubitemid 40189428)
34. Thangarajh M, Masterman T, Hillert J, Moerk S, Jonsson R. A proliferation-inducing ligand (APRIL) is expressed by astrocytes and is increased in multiple sclerosis. Scand J Immunol 2007;65:92-8.
35. Trysberg E, Nylen K, Rosengren LE, Tarkowski A. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum 2003;48:2881-7. (Pubitemid 37280617)
36. Lima I, Melo A, Brandi IV, Costa O, Santiago M. Lupoid sclerosis: what is the role of antiphospholipid antibodies? J Clin Rheumatol 2007;13:85-6.
37. Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Roschke V, et al. Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 2004;63:1096-103. (Pubitemid 39120361)
38. Vallerskog T, Heimburger M, Gunnarsson I, Zhou W, Wahren- Herlenius M, Trollmo C, et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2006;8: R167.
39. Stohl W, Xu D, Kim KS, Koss MN, Jorgensen TN, Deocharan B, et al. BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum 2005;52:2080-91. (Pubitemid 40994331)
40. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999;190:1697-710. (Pubitemid 30002351)
41. Pers JO, Daridon C, Devauchelle V, Jousse S, Saraux A, Jamin C, et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 2005;1050:34-9.
42. Matsushita T, Fujimoto M, Hasegawa M, Tanaka C, Kumada S, Ogawa F, et al. Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF. J Rheumatol 2007;34:2056-62. (Pubitemid 47548210)
43. Morimoto S,Nakano S,Watanabe T, Tamayama Y,Mitsuo A, Nakiri Y, et al. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production. Rheumatology (Oxford) 2007;46:1083-6. (Pubitemid 47050608)
44. Moses N, Wiggers J, Nicholas C, Cockburn J. Prevalence and correlates of perceived unmet needs of people with systemic lupus erythematosus. Patient Educ Couns 2005;57:30-8.
45. Wang B, Gladman DD, Urowitz MB. Fatigue in lupus is not correlated with disease activity. J Rheumatol 1998;25:892-5. (Pubitemid 28210550)
46. Omdal R, Mellgren SI, Koldingsnes W, Jacobsen EA, Husby G. Fatigue in patients with systemic lupus erythematosus: lack of associations to serum cytokines, antiphospholipid antibodies, or other disease characteristics. J Rheumatol 2002;29:482-6. (Pubitemid 34202815)
47. Ronnback L, Hansson E. On the potential role of glutamate transport in mental fatigue. J Neuroinflamm 2004;1:22.
48. Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007;56:4142-50. (Pubitemid 350262342)
49. RamanujamM,Wang X, HuangW, Liu Z, Schiffer L, Tao H, et al. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 2006;116:724-34. (Pubitemid 43326881)